SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Journal of Clinical Oncology · 10.02.2025 · 43 (5) · 536-544
DOI: 10.1200/jco-24-01383 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2025. Verfasst von Rachna T Shroff und 21 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona Cancer Center, Tucson, AZ. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Arizona Cancer Center, Tucson, AZ.
- Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
- SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
- Mayo Clinic Cancer Center, Phoenix, AZ.
- Vanderbilt-Ingram Cancer Center, Nashville, TN.
- Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, VA.
ORCID-Profile: Rachna T Shroff, Gentry King, Aaron J Scott, Mitesh J Borad, Amit Mahipal, Milind M Javle, Puneet Cheema, Anuj Patel, Renuka Iyer, R Katie Kelley, Jaykumar Thumar, Anthony El-Khoueiry, E Gabriela Chiorean, Howard Hochster, Philip A Philip
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Shroff, R. T., King, G., Colby, S., Scott, A. J., Borad, M. J., Goff, L., Matin, K., Mahipal, A., Kalyan, A., Javle, M. M., El Dika, I., Tan, B., Cheema, P., Patel, A., Iyer, R., Kelley, R. K., Thumar, J., El-Khoueiry, A., Guthrie, K. A., …, & Philip, P. A. (2025). SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal of Clinical Oncology, 43(5), 536-544. https://doi.org/10.1200/jco-24-01383
Vancouver
Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, et al. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal of Clinical Oncology. 2025;43(5):536-544. doi:10.1200/jco-24-01383
BibTeX
@article{Shroff2025,
author = {Shroff, Rachna T and King, Gentry and Colby, Sarah and Scott, Aaron J and Borad, Mitesh J and Goff, Laura and Matin, Khalid and Mahipal, Amit and Kalyan, Aparna and Javle, Milind M and El Dika, Imane and Tan, Benjamin and Cheema, Puneet and Patel, Anuj and Iyer, Renuka and Kelley, R Katie and Thumar, Jaykumar and El-Khoueiry, Anthony and Guthrie, Katherine A and Chiorean, E Gabriela and Hochster, Howard and Philip, Philip A},
title = {SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {5},
pages = {536--544},
doi = {10.1200/jco-24-01383}
}
EUVIMED